Biosimilar infliximab: An expert view

Giornale Italiano di Dermatologia e Venereologia

Volumn 150, Issue 4, 2015, Pages 449-459

  Genazzani, A ^a   Altomare, G ^b   Balato, N ^c   Cusano, F ^d   Depita O ^e   Loconsole, F ^f   Micali, G ^g   Piaserico, S ^h   Girolomoni, G ⁱ  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d G RUMMO HOSPITAL   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f POLICLINICO   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

Author keywords

Ankylosing; Arthritis; Biosimilar pharmaceuticals; Dermatology; Infliximab; Rheumatoid; Spondylitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; CREATINE KINASE; DRUG ANTIBODY; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; CT-P13;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANKYLOSING SPONDYLITIS; BINDING AFFINITY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CLINICAL PRACTICE; COST CONTROL; CREATINE KINASE BLOOD LEVEL; CROHN DISEASE; DRUG APPROVAL; DRUG SAFETY; GLYCOSYLATION; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LATENT TUBERCULOSIS; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PSORIASIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION; CHEMISTRY; ITALY; MOLECULAR WEIGHT;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; HUMANS; INFLIXIMAB; ITALY; MOLECULAR WEIGHT;

EID: 84943661371     PISSN: 03920488     EISSN: 18271820     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Agenzia Italiana del Farmaco AIFA. AIFA Position Paper. I farmaci biostimolanti. [Internet] Available from www.agenziafarmaco.gov.it/sites/default/files/AIFA-POSITION-PAPER-FARMACI-BIO-SIMILARI.pdf [cited 2015, Jan 11].
2. European Commission. What you Need to Know about Biosimilar Medicinal Products [Internet]. Available from http://ec.europa.eu/enterprise/sectors/liealthcare/files/docs/biosimilars-report-en.pdf [cited 2015, Jan 11].
3. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G et al. Biosimilars-why terminology matters. Nat Biotechnol 2011;29:690-3.
4. Schneider CK. Biosimilars in rheumatology: The wind of change. Ann Rheum Dis 2013;72:315-8.
5. EMA. Note for guidance on biotechnological/biological products subject to changes in their manufacturing process (CPMP/ICH/5721/03), June 2005.
6. EMA. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010.
7. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8.
8. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-7.
9. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3:209-17.
10. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharma- ceuticals. Nat Biotechnol 2011;29:310-2.
11. EMA. Remsima®: Assessment report [Internet]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Pub-lic-assessment-report/human/002576/WC500151486.pdf [cited 2015, Feb 23].
12. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ et al. Physico- chemical characterization of Remsima®. MAbs 2014;6:1163-77.
13. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
14. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shev-chuk S et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
15. Park W, Miranda P, Brzosko M. Efficacy and Safety of CT-P 13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P 13. ACR/ARHP Annual Meeting 2013, San Diego, 26-30 October.
16. Yoo DH, Prodanovic N, Jaworski J. Efficacy and safety of CT-P 13 (Infliximab Biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P 13 and switching from infliximab to CT-P13. ACR/ARHP Annual Meeting. Oct 25- 30th, 2013. San Diego (USA).
17. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expt Opin Biol Ther 2012;12:1473-85.
18. Brodszky V, Gulacsi L, Vartokne Hever N. Budget impact analysis of biosimilar infliximab treatment for rheumatoid arthritis in six central European countries. ISPOR 2013.
19. Kim JS, Hong JA, Kudrin A. 5 year budget impact analysis of bio- similar infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany. ACR meeting 2014, abstractnumber1166.
20. McCarthy G, Ebel Bitoun C, Guy H. Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland. Value Health 2013;16:a323.
21. No Authors listed. Use of biosimilars reduces treatment costs in RA. Pharmaco Economics & Outcomes News 2013;692:8-30.
22. Whitehouse J, Walsh K, Papandrikopoulou A, Hoad R. The cost saving potential of utilizing biosimilar medicines in biologic naive severe rheumatoid arthritis patients. Value Health 2013;16:a323.